Page 147 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

References
1. Siegel R, Ward E, Brawley O, et al. Cancer 10.
statistics, 2011: The impact of eliminating
socioeconomic and racial disparities on
premature cancer deaths. CA Cancer J Clin
2011;61:212-236.
2. Ries LAG, Young JL, Keel, GE, et al. SEER 11.
Survival Monograph: Cancer Survival
Among Adults: U.S. SEER Program, 1988-
2001, Patient and Tumor Characteristics.
Bethesda, MD: National Cancer Institute;
2007.
3. National Cancer Institute. Cancer Trends 12.
Progress Report - 2009/2010 Update.
Bethesda, MD: National Institutes of Health;
2010.
4. Cooperberg MR, Lubeck DP, Mehta SS, et
al. Time trends in clinical risk stratification
for prostate cancer: implications for
outcomes (data from CaPSURE). J Urol
2003;170:S21-S25.
5. Cooperberg MR, Grossfeld GD, Lubeck DP,
et al. National practice patterns and time
trends in androgen ablation for localized 14.
prostate cancer. J Natl Cancer Inst
2003;95:981-989.
15.
6. Agency for Healthcare Research and
Quality. Methods Reference Guide for
Effectiveness and Comparative
Effectiveness Reviews, Version 1.0. 2010.
Ref Type: Generic
7. Martin RM, Gunnell D, Hamdy F, et al.
Continuing controversy over monitoring 16.
men with localized prostate cancer: a
systematic review of programs in the
prostate specific antigen era. [Review] [45
refs]. Journal of Urology 2006;176:439-449. 17.
8. Ip S, Dvorak T, Yu WW, et al. Comparative
evaluation of radiation treatments for
clinically localized prostate cancer: an
update. Available at:
http://www.cms.gov/mcd/viewtechassess.as
p?where=index&tid=69. August 13, 2010. 18.
Ref Type: Generic
9. Wilt TJ, MacDonald R, Rutks I, et al.
Systematic review: comparative
effectiveness and harms of treatments for 19.
clinically localized prostate cancer. Ann
Intern Med 2008;148:435-448.
93
Moher D, Liberati A, Tetzlaff J, et al.
Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA
statement. Ann Intern Med 2009;151:264-9,
W64.
Stroup DF, Berlin JA, Morton SC, et al.
Meta-analysis of observational studies in
epidemiology: a proposal for reporting.
Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) group. JAMA
2000;283:2008-2012.
Shea BJ, Grimshaw JM, Wells GA, et al.
Development of AMSTAR: a measurement
tool to assess the methodological quality of
systematic reviews. BMC Med Res
Methodol 2007;7:10.
13. Shea BJ, Hamel C, Wells GA, et al.
AMSTAR is a reliable and valid
measurement tool to assess the
methodological quality of systematic
reviews. J Clin Epidemiol 2009;62:1013-
1020.
Altman DG, Bland JM. Presentation of
numerical data. BMJ 1996;312:572.
Owens DK, Lohr KN, Atkins D, et al.
AHRQ series paper 5: grading the strength
of a body of evidence when comparing
medical interventions—agency for
healthcare research and quality and the
effective health-care program. J Clin
Epidemiol 2010;63:513-523.
Mebane C, Gibbs T, Horm J. Current status
of prostate cancer in North American black
males. J Natl Med Assoc 1990;82:782-788.
Hankey BF, Feuer EJ, Clegg LX, et al.
Cancer surveillance series: interpreting
trends in prostate cancer—part I: Evidence
of the effects of screening in recent prostate
cancer incidence, mortality, and survival
rates. J Natl Cancer Inst 1999;91:1017-1024.
Chu KC, Tarone RE, Freeman HP. Trends in
prostate cancer mortality among black men
and white men in the United States. Cancer
2003;97:1507-1516.
Brawley OW. Prostate carcinoma incidence
and patient mortality: the effects of
screening and early detection. Cancer
1997;80:1857-1863.